Clinical magnetocardiography

Fenici, Riccardo; Melillo, G; Masselli, M

doi:10.1007/bf01797748

Cited by 19 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In conclusion, this study demonstrates that although its absolute precision is lower than that achievable with MSRs, MMCG is highly reproducible even in unshielded clinical laboratories, and is accurate enough to be used clinically for noninvasive localization of cardiac arrhythmogenic substrates 2–11 …”

Section: Resultsmentioning

confidence: 73%

“…In clinical practice, MMCG is increasingly used for noninvasive functional cardiac imaging of electrophysiological phenomena and for the localization of the site of origin of cardiac arrhythmias 1–11 . Earlier studies have demonstrated the reproducibility of MMCG cardiac source localization, with point‐like (ECD) and DCI models, when MCGs were recorded in a MSR 13–17 .…”

Section: Discussionmentioning

confidence: 99%

“…Previous investigations have demonstrated that multichannel magnetocardiography (MMCG) can be used for noninvasive functional cardiac imaging and three‐dimensional localization of arrhythmias, and the number of hospitals in which MMCG devices are installed is increasing 1–11 . Until recently, most MMCG systems were reliable only in magnetically shielded rooms (MSRs), and there was great skepticism about the practical clinical usefulness of MMCG (i.e., at a patient's bedside).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Phantom Validation of Multichannel Magnetocardiography Source Localization

Fenici

Brisinda

Nenonen

et al. 2003

Pacing Clinical Electrophis

View full text Add to dashboard Cite

Multichannel magnetocardiography (MMCG) is used clinically for noninvasive localization of the site of origin of cardiac arrhythmias. However, its accuracy in unshielded environments is still unknown. The aim of this study was to test the accuracy of three-dimensional localization of intracardiac sources by means of MMCG in an unshielded catheterization laboratory using a saline-filled phantom, together with a nonmagnetic catheter designed for multiple monophasic action potential recordings in a clinical setting. A nine-channel direct current superconducting quantum interference device (DC-SQUID) system (sensitivity fT/Hz0.5) was used for MMCG from 36 points in a measuring area of 20 x 20 cm. The artificial sources to be localized were dipoles embedded in the distal end of the catheter, placed 12 cm below the sensor's plane. Equivalent current dipoles, effective magnetic dipoles, and distributed currents models were used for the inverse solution. The localization error was estimated as the three-dimensional difference between the physical position of the tip of the catheter and the three-dimensional localization of the dipoles derived by means of the inverse solution calculated from MMCG data. The reproducibility was tested by repeating the MMCG after repositioning the phantom and the measurement system. The average location error of the catheter dipole was 9 +/- 4 mm and was due primarily to imprecise depth estimation. Localization was reproducible within 0.73 mm. The distributed currents model provided an accurate image of current distribution centered over the catheter tip. The authors conclude that MMCG estimation is accurate enough to guarantee proper localization of cardiac dipolar sources even in an unshielded clinical electrophysiological laboratory.

show abstract

Section: Resultsmentioning

confidence: 73%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Phantom Validation of Multichannel Magnetocardiography Source Localization

Fenici

Brisinda

Nenonen

et al. 2003

Pacing Clinical Electrophis

View full text Add to dashboard Cite

show abstract

“…In clinical applications, magnetocardiography has been mainly used for localization of cardiac arrhythmias 23 , 24 , 25 , 26 , 27 and for early diagnosis of myocardial ischemia. 28 , 29 Furthermore, early reports in literature have described its potential in detecting heart transplant rejection, suggesting a potential role in detecting myocardial inflammation.…”

mentioning

confidence: 99%

Application of Magnetocardiography to Screen for Inflammatory Cardiomyopathy and Monitor Treatment Response

Brala

Thevathasan

Grahl

et al. 2023

JAHA

View full text Add to dashboard Cite

Background Inflammatory cardiomyopathy is one of the most common causes of sudden cardiac death in young adults. Diagnosis of inflammatory cardiomyopathy remains challenging, and better monitoring tools are needed. We present magnetocardiography as a method to diagnose myocardial inflammation and monitor treatment response. Methods and Results A total of 233 patients were enrolled, with a mean age of 45 (±18) years, and 105 (45%) were women. The primary analysis included 209 adult subjects, of whom 66 (32%) were diagnosed with inflammatory cardiomyopathy, 17 (8%) were diagnosed with cardiac amyloidosis, and 35 (17%) were diagnosed with other types of nonischemic cardiomyopathy; 91 (44%) did not have cardiomyopathy. The second analysis included 13 patients with inflammatory cardiomyopathy who underwent immunosuppressive therapy after baseline magnetocardiography measurement. Finally, diagnostic accuracy of magnetocardiography was tested in 3 independent cohorts (total n=23) and 1 patient, who developed vaccine‐related myocarditis. First, we identified a magnetocardiography vector to differentiate between patients with cardiomyopathy versus patients without cardiomyopathy (vector of ≥0.051; sensitivity, 0.59; specificity, 0.95; positive predictive value, 93%; and negative predictive value, 64%). All patients with inflammatory cardiomyopathy, including a patient with mRNA vaccine‐related myocarditis, had a magnetocardiography vector ≥0.051. Second, we evaluated the ability of the magnetocardiography vector to reflect treatment response. We observed a decrease of the pathologic magnetocardiography vector toward normal in all 13 patients who were clinically improving under immunosuppressive therapy. Magnetocardiography detected treatment response as early as day 7, whereas echocardiographic detection of treatment response occurred after 1 month. The magnetocardiography vector decreased from 0.10 at baseline to 0.07 within 7 days ( P =0.010) and to 0.03 within 30 days ( P <0.001). After 30 days, left ventricular ejection fraction improved from 42.2% at baseline to 53.8% ( P <0.001). Conclusions Magnetocardiography has the potential to be used for diagnostic screening and to monitor early treatment response. The method is valuable in inflammatory cardiomyopathy, where there is a major unmet need for early diagnosis and monitoring response to immunosuppressive therapy.

show abstract

“…During the last decade Magnetocardiographic (MCG) mapping has been increasingly used as a clinical method for non invasive three-dimensional localization of cardiac arrhythmogenic substrates [1][2][3][4][5][6][7][8][9][10][11][12][13][14]. In order to achieve the best signal-to-noise ratio, in the majority of hospital expensive multichannel systems have been installed, which require heavy electromagnetic shielding.…”

Section: Introductionmentioning

confidence: 99%